Drug Profile
BI 411034
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in Germany (PO, Liquid)
- 01 Aug 2012 Boehringer Ingelheim completes a phase I trial in healthy volunteers in Germany (NCT01581684)
- 19 Apr 2012 Phase-I clinical trials in Undefined indication in Germany (PO)